A form of brain cancer long considered nearly untreatable has shown a surprising response in an experimental therapy trial. In 2024, doctors at Mass General Brigham tested a modified version of CAR-T immunotherapy on three patients with recurrent Glioblastoma, one of the most difficult cancers to treat.

The researchers used a new approach that combined engineered CAR-T immune cells with targeted antibodies, aiming to help the immune system recognize and attack tumor cells more effectively. The treatment was delivered directly into the fluid surrounding the brain and spinal cord, bringing the immune cells into close contact with the cancer.

Early results surprised the medical team. One patient’s tumor shrank significantly within days and continued to decrease over several weeks, while the other patients also showed rapid tumor regression on MRI scans shortly after treatment.

Although the study involved only three people and remains in very early stages, the findings offer cautious hope. For a disease historically associated with very limited treatment options, the trial suggests that innovative immunotherapy strategies may eventually open new possibilities for fighting glioblastoma.